Abstract: The invention relates to methods of treating and preventing radiation damage from whole-body exposure. According to the methods of the invention, subjects are treated therapeutically and/or prophylactically with low-anticoagulant heparinoids. The invention also relates to methods of extending the life of subjects exposed to whole-body radiation.

Abstract: Methods and compositions are presented for mobilizing hematopoietic stem cells (HSC) and for mobilizing T lymphocytes from the bone marrow and other compartments; use of the mobilized HSCs for HSC transplantation and mobilized T lymphocytes for T cell immunotherapy; for enhancing engraftment of transplanted HSCs and transferred T cells; and for enhancing recovery of hematopoietic system function following HSC transplantation or for enhancing engraftment and/or persistence of T cells following transfer for T cell immunotherapy.

Abstract: Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.

Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Abstract: The present application is directed to systems and methods for an information delivery system for a container. At least one machine readable indicia may be printed on an outer surface of the container. A top label may cover at least a portion of the outer surface of the container. The top label may be rotatable about the outer surface of the container. The top label may have a transparent window allowing at least one of the machine readable indicia to be visible through the transparent window.

Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Abstract: The present application is directed to a rotating shrink label measurement systems for a container and methods thereof. A base label may be adhered to the container, and measurement information displayed on the base label. A top label may cover at least a portion of the base label. The top label may be rotatable about the base label to a specific unit of measurement. The top label may have a transparent window allowing measurement information for the specific unit of measurement to be visible through the transparent window. The container and top label may be enclosed by a tamper evident sleeve.

Abstract: The present application is directed to container and shrink label systems. The container may comprise multiple label locking features that hold a shrink label in place on a conically-shaped container. The system may further comprise an interactive promotional label system comprising multiple promotional elements that may be linked to complete a promotional event.

Abstract: The present application is directed to systems and methods for an information delivery system for a container. At least one machine readable indicia may be printed on an outer surface of the container. A top label may cover at least a portion of the outer surface of the container. The top label may be rotatable about the outer surface of the container. The top label may have a transparent window allowing at least one of the machine readable indicia to be visible through the transparent window.

Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Abstract: Documents are published in a publish subscribe data processing system. A first document to be published may have an associated topic. The first document is retained as a retained document. A second document to be published is retained as the retained document in response to receiving the second document before a predetermined time interval has passed. A copy of the second document is sent to a subscriber of the topic. A copy of the retained document is sent to the subscriber of the topic in response to a determination that the predetermined time interval has passed.

Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Abstract: The present invention contemplates a variety of techniques including a computer implemented method. The method comprises receiving a plurality of offers from a plurality of entities, combining offers from the plurality of offers into an offer stack, wherein all offers of the offer stack can be applied jointly to a transaction and presenting the offer stack to a customer. Some of the entities can have one or more membership programs, and offers can be presented in one or more membership programs.

Abstract: A light-driven electrolytic cell that uses water vapor as the feedstock and that has no wires or connections whatsoever to an external electrical power source of any kind. In one embodiment, the electrolytic cell uses a proton exchange membrane (PEM) with an IrRuOx water oxidation catalyst and a Pt black water reduction catalyst to consume water vapor and generate molecular oxygen and a chemical fuel, molecular hydrogen. The operation of the electrolytic cell using water vapor supplied by a humidified carrier gas has been demonstrated under varying conditions of the gas flow rate, the relative humidity, and the presence or absence of oxygen. The performance of the system with water vapor was also compared to the performance when the device was immersed in liquid water.

Abstract: The present application provides methods for the treatment of cancer, comprising administering substantially non-anticoagulant 2-O, 3-O desulfated heparin to patients suffering from cancer that is, or can become resistant to, cancer treatment, such as chemotherapy, targeted cancer therapy, or radiation therapy. The compositions can be administered to sensitize, or to reverse resistance to, cancer treatment, and can be administered alone or in combination with cancer treatment to subjects with solid tumors including, but not limited to, pancreatic, breast, renal, colorectal, gastric, or esophageal cancer, and subjects with hematologic malignancies, including but not limited to leukemia and lymphoma.

Abstract: A system for three-dimensionally storing and encoding information in an optical storage medium. Information at a surface location is encoded according to the surface depth or width of the location. The information is then retrieved through the use of intensity measurements of light modulated by the depth or width of the storage location. The intensity of the light represents the data value stored at the location.

Abstract: A pulsed laser radar apparatus utilizing a Q-switched laser unit to generate laser pulse signals including a low intensity trailing tail. The trailing tail is utilized to provide a local oscillator signal that is combined with the target return signal prior to detection in a heterodyned detector unit.